Summary
We have carried out a phase II trial to evaluate the efficacy and toxicity of a combination therapy consisting of mitoxantrone 10 mg/sqm i.v. on day 1, levo-leucovorin 250 mg/sqm administered over 2 hours and 5-fluorouracil 500 mg/sqm i.v. push after the first hour of levo-leucovorin infusion, on days 15–16 (MFL) in patients aged more than 65 years. 24 patients with advanced breast cancer entered the study: 16 aged 65–70 yrs, 4 patients 70–75 yrs, and 4 > 75 yrs. Median PS was 1 (range 0–2); sites of metastases were: bone 14 patients, viscera 14 patients, soft tissue 11 patients, and CNS 1 patient. A median number of 6 cycles (range 3–9) was administered. All patients were evaluable for response and toxicity; partial response was obtained in 12 (50%) patients (95% C.I 30–70), stable disease was observed in 9 patients (37.5%), while 3 patients (12.5%) progressed. Median progression-free survival and survival were 9 months (range 2–14) and 14 months (range 5–36), respectively. Toxicity was generally mild and the most frequently observed side-effects were WHO gr. 1–2 leukopenia in 6/24 (25%) patients and gr. 1–2 emesis in 10/24 (41.6%) pts. 1 patient pretreated with doxorubicin cumulative dose of 240 mg/sqm showed clinical signs of congestive heart failure (NYHA grade 1) after the fifth cycle of treatment. MFL is a well tolerated regimen and could represent a safe and effective treatment in older advanced breast cancer patients.
References
Moolgavkar SH, Stevens RG, Lee JEV: Effects of age on 493–501, 1979
Office of Population Censuses and Surveys: Cancer Statistics Registrations, series MBI M012. London, United Kingdom, Her Majesty's Stationery Office, pp 6–7, 1980
Begg CB, Carbone PP: Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group: Cancer 52, 1986
Canellos GP, De Vita VT, Gold GL: Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med 84: 389–392, 1976
Falkson G, Gelman RS, Tormey DC: The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 56: 219–224, 1985
Herrmann R, Knuth A, Kleeberg U: Randomized multicenter trial of sequential methotrexate and 5-fluorouracil vs FU alone in metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 9: 102, 1990
Petrelli N, Herrera L, Rustum Y: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559–1565, 1987
Ardaland B, Singh G, Silberman H: A randomized phase I and II study of short term infusion of high dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancer. J Clin Oncol 6: 1053–1058, 1988
Erlichman C, Fine S, Wong A: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469–475, 1988
Swain SM, Lippman ME, Egan EF: 5-fluorouracil and high dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890–899, 1989
Doroshow JH, Leong L, Margolin K: Refractory metastatic breast cancer: salvage therapy with fluorouracil and high dose continous infusion leucovorin-calcium. J Clin Oncol 7: 439–444, 1989
Loprinzi CL, Ingle JN, Schaid DJ: 5-fluorouracil plus leucovorin in women with metastatic breast cancer: a phase II study. Am J Clin Oncol 14: 30–32, 1991
Zaniboni A: The emerging role of 5-fluorouracil and leucovorin in the treatment of advanced breast cancer. A review. J Chemother 1: 330–337, 1989
Yap HY, Blumenschein GR, Schell FC: Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Intern Med 95: 694–697, 1981
Henderson IC, Allegra JC, Woodcock T: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560–571, 1989
Bennett JM, Muss HB, Doroshow JH: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast cancer. J Clin Oncol 6: 1611–1620, 1988
Hainsworth JD, Andrews MB, Johnson DH: Mitoxantrone, fluorouracil and high dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. J Clin Oncol 9: 1731–1735, 1991
Jones ES, Mennel RG, Brooks B: Phase II study of mitoxantrone, leucovorin and infusional fluorouracil for treatment of metastatic breast cancer. J Clin Oncol 9: 1736–1739, 1991
Mammoliti S, Merlini L, Caroti C, Gallo L: Mitoxantrone, 5-fluorouracil and levo-leucovorin as salvage treatment in advanced breast cancer patients. Eur J Cancer 30A, N 2: 298–299, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mammoliti, S., Merlini, L., Caroti, C. et al. Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients. Breast Cancer Res Tr 37, 93–96 (1996). https://doi.org/10.1007/BF01806636
Issue Date:
DOI: https://doi.org/10.1007/BF01806636